These observations demonstrate the potential clinical relevance of targeting R-spondins in the treatment of colorectal tumors, and correspondingly an anti-RSPO3 antibody [30] developed to target the R-spondin pathway is currently in phase I clinical trial. Here, RSPO1 is linked to colorectal neoplasm.